Patients clinical characteristics at baseline
| Low vWF:Ag (N=42) | High vWF:Ag (N=41) | Total (N=83) | P value | |
| Age | >0.05 | |||
| Mean (SD) | 62.27 (16.62) | 67.63 (14.42) | 64.95 (15.70) | |
| Sex | >0.05 | |||
| Female | 12 (28.6%) | 16 (39.0%) | 28 (337%) | |
| Male | 30 (71.4%) | 25 (61.0%) | 55 (66.3%) | |
| ECOG | =0.039 | |||
| 0 | 36 (85.7%) | 26 (65.0%) | 62 (75.6%) | |
| 1+2 | 6 (14.3%) | 14 (35.0%) | 20 (24.4%) | |
| Primary melanoma site | >0.05 | |||
| CUP | 7 (16.7%) | 8 (19.5%) | 15 (18.1%) | |
| Cutaneous | 28 (66.7%) | 28 (68.3%) | 56 (67.5%) | |
| Mucosal | 5 (11.9 %) | 3 (7.3%) | 8 (9.6%) | |
| Uveal | 2 (4.8%) | 2 (4.9%) | 4 (4.8%) | |
| AJCC | >0.05 | |||
| III | 3 (7.1%) | 4 (9.8%) | 7 (8.4%) | |
| IV | 39 (92.9%) | 37 (90.2%) | 76 (91.6%) | |
| Metastatic classification | >0.05 | |||
| M0 | 6 (14.3%) | 4 (9.8%) | 10 (12%) | |
| M1a | 5 (11.9%) | 5 (12.2%) | 10 (12%) | |
| M1b | 13 (31.0%) | 9 (22.0%) | 22 (26.5%) | |
| M1c | 9 (21.4%) | 15 (36.6%) | 24 (28.9%) | |
| M1d | 9 (21.4%) | 8 (19.5%) | 17 (20.5%) | |
| Prior Therapies | >0.05 | |||
| No | 30 (71.4%) | 24 (58.5%) | 54 (65.1%) | |
| Yes | 12 (28.6%) | 17 (41.5%) | 29 (34.9%) | |
| Mutation status | =0.045 | |||
| BRAF | 20 (47.6%) | 10 (24.4%) | 23 (40.4%) | |
| NRAS | 5 (11.9%) | 12 (29.3%) | 16 (28.1%) | |
| None | 17 (40.5%) | 19 (46.3%) | 18 (31.6%) | |
| Baseline therapy | >0.05 | |||
| Anti-PD1 | 12 (28.6%) | 12 (28.6%) | 24 (28.9%) | |
| Combination | 30 (71.4%) | 29 (70.7%) | 59 (71.1%) |
Clinical characteristics are reported for the entire cohort but also for the patients of each median group of vWF:Ag levels. P values of Fisher test for categorical variables and Wilcoxon test for continuous variables between low and high vWF:Ag groups are reported.
AJCC, American Joint Committee on Cancer; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of normal.